Ethylbromazolam: review of the evidence on its use and harms
The report reviews the evidence on the use and harms of the novel benzodiazepine ethylbromazolam and recommends control under the Misuse of Drugs Act 1971.
This file may not be suitable for users of assistive technology.
Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
This file may not be suitable for users of assistive technology.
Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
This file may not be suitable for users of assistive technology.
Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
Details
Based on the review of the currently available evidence, the Advisory Council on the Misuse of Drugs (ACMD) recommends:
making ethylbromazolam a Class C drug
adding ethylbromazolam to Schedule 1 of the Misuse of Drugs Regulations 2001
The government responded to the recommendations on 6 July 2026.